A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection

Area of Science:

• Microbiology
• Vaccinology
• Immunology

Background:

• Clostridioides difficile infection (CDI) poses a significant public health challenge.
• Current preventative strategies for CDI are limited.

Purpose of the Study:

• To develop and evaluate a novel messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine against C. difficile.
• To assess the vaccine's efficacy in preventing and treating CDI and promoting bacterial decolonization.

Main Methods:

• Development of a multivalent mRNA-LNP vaccine targeting C. difficile toxins and virulence factors.
• Evaluation of immune responses (humoral and cellular) in animal models.
• Assessment of protection against lethal CDI in primary and recurrent infection models.
• Investigation of the vaccine's impact on C. difficile decolonization.

Main Results:

• The mRNA-LNP vaccine induced robust, long-lived systemic and mucosal immune responses.
• Vaccination provided protection against lethal CDI in mice.
• Inclusion of non-toxin antigens enhanced C. difficile decolonization from the gastrointestinal tract.
• Immune responses were independent of alterations in the intestinal microbiota.

Conclusions:

• mRNA-LNP vaccine technology is a viable platform for developing novel C. difficile therapeutics.
• The vaccine demonstrates potential for limiting acute CDI and promoting bacterial decolonization.
• This approach offers a promising strategy to combat the urgent public health threat of CDI.